Abundant Produce receives boost from government to fast-track plant R&D
Abundant Produce Limited (ASX:ABT), the only plant breeding company listed on the ASX, has today announced some good news surrounding grants and rebates.
As is custom for a small cap like ABT, it has received a Research and Development (R&D) Tax Incentive from the government — this time to the sum of ~A$630,000, which is an increase on the previous estimate of $250,000.
Further, the NSW Government’s TechVouchers program will fund a $20,000 project in collaboration with the University of NSW for the Taste of Research Programme and R&D for ABT’s Lycopene ActiveLycoTM products.
A third source of funds of over $50,000 will also be received by ABT imminently, thanks to an Export Markets Development Grant (EMDG) return, and a further $110,000 will be coming the company’s way via an Innovations Connections grants from the Australian Government which will fund a new graduate and R&D for future products.
It should be noted here that ABT remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
Tony Crimmins, ABT’s Group CEO commented on today’s positive news: “As a commercialisation company developing new IP for vegetable seed and varieties and lifestyle nutraceuticals, it is important that we increase shareholder value through applications for government funding. There are a number of grant facilities on a federal and state level available to ABT to reduce the impact of costs associated with development and overseas exportation of new innovative products.”
The R&D Tax Incentive provides a tax benefit to help companies like ABT offset the cost of conducting eligible research and development activities. Through the program, the government provides a return of up to 150 per cent of costs. A rebate is based on the tax rate for the company, which currently stands at 30 per cent.
Further government funds through TechVouchers and EMDG
Administered by the NSW Government, TechVouchers NSW links universities with companies to enable innovative joint research projects. ABT lodged an application to assess the feasibility of supercritical fluid extraction for our Lycopene ActiveLycoTM and received $20,000. With this fiscal support, ABT’s Abundant Natural Health division can deliver its products to the Chinese and Australian markets.
The government’s Export Markets Development Grant is an export grant provided to companies that are extending their reach on a global scale. ABT has been exporting seed to the USA, UK and the Middle East for two years and is looking to develop its export revenues further. To assist in ABT’s international success, the Federal Government’s Austrade division has refunded 50 per cent of the company’s export-associated costs — to the amount of $50,000.
An additional $110,000 in grants will assist in funding to develop lycopene extraction processes, as well as expenses relating to Chemical Engineering graduate Mitchell Austin from Sydney University.
“It is reassuring that the State and Federal Governments are recognising ABT’s innovative work through the TechVoucher and Boosting Business Innovation Programme as well as Innovation Connections, which have helped us accelerate our research and scale up both locally and internationally,” Crimmins said.
“We have built solid collaborative relationships with UNSW and The University of Sydney here in Australia and Chonnam National University in Korea allowing us to tap into some of the best high tech equipment and technical expertise globally. Essentially, it promotes innovation and collaboration between our business and the scientific research sector.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.